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Cerebrospinal ﬂuid markers including trefoil factor 3 are
associated with neurodegeneration in amyloid-positive
individuals
RW Paterson1, JW Bartlett2, K Blennow3, NC Fox1, Alzheimer’s Disease Neuroimaging Initiative6, LM Shaw4, JQ Trojanowski4,
H Zetterberg3,5 and JM Schott1
We aimed to identify cerebrospinal ﬂuid (CSF) biomarkers associated with neurodegeneration in individuals with and without CSF
evidence of Alzheimer pathology. We investigated 287 Alzheimer’s Disease Neuroimaging Initiative (ADNI) subjects
(age= 74.9 ± 6.9; 22/48/30% with Alzheimer’s disease/mild cognitive impairment/controls) with CSF multiplex analyte data and
serial volumetric MRI. We calculated brain and hippocampal atrophy rates, ventricular expansion and Mini Mental State Examination
decline. We used false discovery rate corrected regression analyses to assess associations between CSF variables and atrophy rates
in individuals with and without amyloid pathology, adjusting in stages for tau, baseline volume, p-tau, age, sex, ApoE4 status and
diagnosis. Analytes showing statistically signiﬁcant independent relationships were entered into reverse stepwise analyses.
Adjusting for tau, baseline volume, p-tau, age, sex and ApoE4, 4/83 analytes were signiﬁcantly independently associated with brain
atrophy rate, 1/83 with ventricular expansion and 2/83 with hippocampal atrophy. The strongest CSF predictor for the three atrophy
measures was low trefoil factor 3 (TFF3). High cystatin C (CysC) was associated with higher whole brain atrophy and hippocampal
atrophy rates. Lower levels of vascular endothelial growth factor and chromogranin A (CrA) were associated with higher whole
brain atrophy. In exploratory reverse stepwise analyses, lower TFF3 was associated with higher rates of whole brain, hippocampal
atrophy and ventricular expansion. Lower levels of CrA were associated with higher whole brain atrophy rate. The relationship
between low TFF3 and increased hippocampal atrophy rate remained after adjustment for diagnosis. We identiﬁed a series of CSF
markers that are independently associated with rate of neurodegeneration in amyloid-positive individuals. TFF3, a substrate for
NOTCH processing may be an important biomarker of neurodegeneration across the Alzheimer spectrum.
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INTRODUCTION
Although Alzheimer’s disease (AD) is a relentless progressive
condition there is considerable variation in the rate of progression
between individuals.1 Previous studies have suggested that
atrophy rates may be affected by the age of onset,2 disease
severity,3 by the concurrence of other pathologies including
vascular disease4 and TDP43 burden.5 However, the majority of
the variance in rates of atrophy between individuals remains
unaccounted for.6 A more detailed understanding of factors
inﬂuencing this variability could allow for prognostication for
patients, and aid in clinical trial design or interpretation where
interindividual variance in atrophy rate increases required sample
sizes;6 and provide insights into the underlying biology of AD, in
turn leading to the discovery of new targets for disease prevention
strategies. Biomarkers provide a means both of quantifying the
rate of disease progression and exploring its inﬂuences. Rates of
atrophy, either of brain or brain substructures can be measured
with a high degree of precision from serially acquired MRI and
provide a robust measure of progression which correlates with
cognitive decline.7 Cerebrospinal ﬂuid (CSF) can be used to assess
neuronal, synaptic, inﬂammatory, and other proteins involved, or
potentially involved, in AD pathogenesis.8 To date, Aβ1-42 and tau
are routinely measured as AD biomarkers,8 with good evidence
that these are markers of AD pathology and predict cognitive
decline in mild cognitive impairment.9 What is less clear however
is which CSF markers best reﬂect rates of neuronal damage or loss
in AD—and therefore may be useful predictors of progression. A
previous exploratory pilot study of CSF biomarkers in healthy
elderly with amyloid pathology identiﬁed a number of analytes
that may predict atrophy in speciﬁc brain regions.10 In this study
we aimed to assess whether any analytes in a large panel of CSF
biomarkers were associated with increased rates of atrophy across
the Alzheimer spectrum.
PATIENTS AND METHODS
Subjects
We investigated subjects from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) (adni.loni.ucla.edu), a multicenter publicly/privately funded
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longitudinal study of individuals with AD, amnestic mild cognitive
impairment (MCI) and normal cognition. Institutional review boards
approved the study and subjects gave written consent. Subjects under-
went baseline and periodic clinical and neuropsychological assessment
and serial MRI. Approximately 60% had CSF. A selected group had
additional CSF analysis for the ADNI Biomarkers Consortium project ‘Use of
Targeted Multiplex Proteomic Strategies to Identify Novel Cerebrospinal
Fluid (CSF) Biomarkers in AD’ as described on the ADNI website. We
downloaded data from LONI (http://adni.loni.ucla.edu) that included all
subjects with this supplementary CSF multiplex data. As our aim was to
explore factors inﬂuencing atrophy rates in individuals with AD pathology
we dichotomised subjects using a baseline CSF Aβ1-42 level of 192
pgml− 1, a level shown to distinguish individuals with autopsy conﬁrmed
AD pathology and controls with ~ 96% sensitivity and ~ 77% speciﬁcity.11
We excluded subjects who did not have useable 1.5T MRI scans at baseline
and 1 year, and one subject without a deﬁned diagnosis. We recorded
ApoE status and genotype at the rs7280100 SNP, which has been identiﬁed
a candidate locus for trefoil factor 3 (TFF3),12 as well as Mini Mental State
Examination (MMSE) at baseline and 12 months.
Cerebrospinal ﬂuid
CSF collection, processing and storage procedures have previously been
described.11 Processing, aliquoting and storage was carried out according
to the ADNI Biomarker Core Laboratory Standard Operating Procedures
(http://adni-info.org/Scientists/Pdfs/adniproceduresmanual12.pdf). Sam-
ples were analyzed using a multiplex-based immunoassay panel based
upon Luminex immunoassay technology developed by Rules Based
Medicine (MyriadRBM, Austin, TX, USA). CSF Aβ1-42, total tau (t-tau) and
phosphorylated tau (p-tau) and a panel of 159 analytes including
inﬂammatory, metabolic, lipid and other disease relevant analytes were
tested. Data were prepared for analysis according to the biomarkers
consortium statistical analysis plan (http://adni.loni.ucla.edu/wp-content/
uploads/2012/01/2011Dec28-Biomarkers-Consortium-Data-Primer-FINAL1.
pdf), and as previously described.13 Of 159 analytes, 76 had greater than
10% of quality control data missing, leaving 83 available for analysis. For
each analyte, the normality of data was assessed by the ADNI Biomarkers
Consortium: non-normal data were transformed using the Box and Cox
technique.14
Image acquisition
Details of the MRI methodology have previously been described.15 T1
weighted, inversion-recovery prepared structural images were acquired at
baseline and 12 months on 1.5T MRI units using standardized protocols.
Corrections for distortion due to gradient nonlinearity and for image
intensity non-uniformity and scalings were made based on phantom
measures. Images underwent central quality control evaluation for
protocol compliance and internal quality control at the Dementia Research
Centre.
Volume loss measurement
Image analysis was performed using in-house MIDAS software.16 Whole
brain and lateral ventricles were delineated semi-automatically and
hippocampal volumes were measured using the automated HMAPS
method.17 Volume loss (ml) between scans was obtained using the
boundary shift integral (BSI) following a 9-degrees-of-freedom registration
and differential bias correction of the follow-up to baseline scans. For
lateral ventricles and hippocampi, change over time was quantiﬁed using
the ventricular (VBSI)18 and hippocampal BSI (HBSI)17 respectively. Rates of
volume loss were annualized using the interscan interval.
Statistical analysis
To assess the relationship between CSF analytes and rates of brain volume
change, we ﬁtted separate regression models for rates of ventricular
expansion, brain and hippocampal atrophy for each CSF variable, including
baseline volume (brain, ventricular and hippocampal volume, respectively)
and tau as covariates in both the amyloid positive and negative groups.
Subsequent analyses in the amyloid-positive group alone were repeated
including age, gender, APOE4 status and phospho-tau (p-tau) as additional
covariates and ﬁnally also adjusting for baseline diagnosis (AD, MCI,
control). We used an implementation of the false discovery rate (FDR)
procedure19 with control at the 5% level to correct for multiple
comparisons, and report the adjusted regression coefﬁcients between
each atrophy rate and those CSF variables showing FDR signiﬁcant
relationships. We then performed three exploratory reverse stepwise
regression analyses to identify combinations of CSF analytes indepen-
dently predicting increased rates of change for each measure, using FDR
signiﬁcant CSF variables identiﬁed in the preceding step and the three sets
of adjustment variables. In each stepwise analysis, the corresponding
adjustment variables were forced to be included in regression models.
Finally, we assessed whether CSF analytes were associated with cognitive
function. We ﬁrst established whether there was a decline in MMSE
between baseline and 12 months that was signiﬁcantly different from zero.
We then determined if atrophy rates and decline in MMSE scores at
12 months were correlated using separate regression models for rates of
ventricular expansion, brain and hippocampal atrophy. We then ﬁtted
separate regression models for annualized change in MMSE score and
each CSF variable found to be (after FDR control) associated with at least
one atrophy measure.
The FDR procedure used was derived assuming independence between
test statistics.19 However, it has been shown that the procedure is valid
under certain types of dependence,20 and in a simulation study (results not
shown) matching the analysis used here, the procedure correctly
controlled the FDR at 5%.
To quantify the unadjusted group discrimination ability of the analytes
that were FDR signiﬁcant adjusted for baseline brain volumes, sex, age,
APOE4 status, tau and p-tau the area under the ROC curve for detecting
between AD and control groups was estimated.
RESULTS
Baseline group characteristics
A ﬂow chart outlining subject inclusion is provided in Figure 1
The demographics, genetic characteristics, cognitive scores and
atrophy measures of the 287 subjects included in this analysis are
described in Table 1. The mean± s.d. age of this group was
74.9 ± 6.9 years, 21.6% had a clinical diagnosis of AD, 48.1% MCI
and 30.3% were controls. Eighty-three CSF analytes as well as CSF
tau, Aβ1-42 and p-tau were available for analysis (Supplementary
Table 1).
Analytes predicting atrophy
In subjects without evidence for signiﬁcant amyloid deposition,
that is, those with baseline CSF Aβ1-42 4192 pgml− 1, after
adjusting for baseline brain volumes and CSF t-tau and with FDR
correction to control for multiple comparisons, none of the CSF
analytes was signiﬁcantly associated with any of the atrophy
measures.
In subjects with CSF Aβ1-42 ⩽ 192 pgml− 1, after adjusting for
baseline volumes and t-tau and with FDR correction to control for
multiple comparisons, 10/83 analytes were associated with whole
brain atrophy rate, 45/83 analytes with ventricular expansion rate,
and 4/83 with hippocampal atrophy rate (Table 2). After
additionally adjusting for p-tau, age, ApoE status and sex and
with FDR correction to control for multiple comparisons, 4/83
287 ADNI subjects recruited to ADNI 1 
with extended CSF analysis and 
Volumetric MRI at baseline and 12 
months satisfying central quality 
control evaluation for protocol 
compliance and internal quality control 
at the Dementia Research Centre
Baseline CSF Aβ1-42 ≤192pg/ml
(200 subjects)
Baseline CSF Aβ1-42 >192pg/ml
(87 subjects)
Figure 1. Subjects included in analysis. ADNI, Alzheimer's Disease
Neuroimaging Initiative; CSF, cerebrospinal ﬂuid.
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analytes were associated with whole brain atrophy rate, 1/83
analyte with ventricular expansion rate, and 2/83 with hippocam-
pal atrophy rate (Table 2). These relationships are illustrated using
scatter plots in Figure 2. After additionally adjusting for baseline
diagnosis, only 2/83 analytes were associated with hippocampal
atrophy, and none with brain atrophy or ventricular expansion
(Table 2).
Lower levels of TFF3 were consistently associated with greater
ventricular expansion (Po0.001), hippocampal atrophy rate
(Po0.001) and whole brain atrophy rate (Po0.001) even after
adjusting for baseline brain volumes, t-tau, p-tau, age, APOE status
and sex. After additionally adjusting for baseline diagnosis, lower
levels of TFF3 were still associated with higher hippocampal
atrophy (P = 0.007). Higher levels of Cystatin C (CysC) were
positively associated with all three atrophy measures after
adjusting for baseline brain volumes and t-tau and remained
predictive of higher whole brain (P= 0.009) and hippocampal
atrophy (P = 0.034) after adjusting for p-tau, age, ApoE status and
sex. Lower levels of vascular endothelial growth factor (VEGF) were
positively associated with all three atrophy measures after
adjusting for baseline brain volumes and t-tau and remained
associated with higher whole brain atrophy (P= 0.023) after
adjusting for p-tau, age, APOE status and sex. Lower levels of
Chromogranin-A (CgA) were associated with higher whole brain
atrophy (0.008) and ventricular expansion (0.009) after adjusting
for baseline volumes and t-tau and predicts higher whole brain
atrophy (P= 0.009) after additionally adjusting for p-tau, age, ApoE
status and sex.
In exploratory reverse stepwise models that included only those
variables showing FDR signiﬁcant associations in the initial
analyses (Table 3), lower levels of TFF3 were associated with
higher rates of whole brain atrophy, ventricular expansion and
hippocampal atrophy, even when, p-tau, age, APOE status and sex
were included in the model. Lower levels of CgA were associated
with higher whole brain atrophy and ventricular expansion when
t-tau and baseline volume were included in the model; and with
higher whole brain atrophy when p-tau, age, APOE status and sex
were also included as covariates. In addition, adjusting for baseline
diagnosis, TFF3 was the only analyte independently associated
with hippocampal atrophy rate; and no analytes were (indepen-
dently) associated with whole brain atrophy or ventricular
expansion.
Twenty-three of the subjects had a minor allele at the
rs7280100 locus (predicted to reduce CSF TFF3). These individuals
had 18% higher rates of ventricular expansion, 14% higher rates of
brain atrophy and 30% higher rates of hippocampal atrophy
compared with noncarriers, the latter reaching borderline
signiﬁcance after adjustment for baseline diagnosis, (P = 0.07).
Table 1. Baseline demographics, ApoE genotype, cognitive proﬁles, CSF proﬁles, brain volumes and 1 year atrophy rates of 200 subjects with Aβ1-
42≤ 192 pgml− 1 and 87 subjects with Aβ1-424192 pgml− 1
Subjects with Aβ1-42 ≤ 192 pg ml− 1 (n= 200)
Combined Controls (n=33) MCI (n= 108) AD (n=59)
Age at CSF exam (years) 74.8± 6.7 76.5± 5.5 74.4± 7.0 74.5± 7.4
Gender (% male) 59.4 54.5 63.9 52.5
APOE4 positive (%) 65.5 51.5 69.0 78.0
MMSE (mean) 26.1± 2.5 29.1± 0.1 26.7± 1.8 23.5± 1.8
Modiﬁed ADAS-cog 13.1± 6.2 7.1± 3.4 12.1± 4.6 18.5± 6.1
Aβ1-42 (pgml− 1) 137.2± 22.7 146.5± 25.5 136.5± 29.0 133.1± 23.2
t-tau (pgml− 1) 114.4± 55.3 82.5± 30.7 115.3± 56.0 130.7± 57.7
p-tau (pgml− 1) 39.5± 17.5 31.2± 17.4 39.8 ± 15.4 43.6± 19.8
KBSI (ml per year) 13.8± 8.7 8.9± 7.3 14.2± 9 15.7± 7.8
VBSI (ml per year) 3.8± 3.1 2.1± 2.0 3.8± 3.1 4.9± 3.1
HBSI (ml per year) 0.15± 0.10 0.08± 0.1 0.1± 0.1 0.2± 0.1
MMSE decline from baseline to 12 months (points per year; n= 199) 1.7± 3.5 0.4± 1.7 1.4± 2.7 3.0± 4.8
% of individuals with minor allele rs7280100 12.2 12.5 10.9 14.6
Subjects with Aβ1-424192 pg ml− 1 (n= 87)
Combined Controls (n=54) MCI (n=30) AD (n= 3)
Age at CSF exam (years) 75.4± 6.3 74.9± 5.2 75.5± 8.0 81.4± 6
Gender (% male) 62.1 50 80 100
APOE4 positive (%) 89.6 90.7 86.7 100.0
MMSE (mean) 28.3± 1.7 29.0± 1.0 27.2± 1.9 25.3± 1.2
Modiﬁed ADAS-cog 7.6± 1.4 5.7± 2.5 10.5± 3.8 14.4± 6.8
Aβ1-42 (pgml− 1) 244.4± 26.1 243.1± 25.6 246.5± 26.0 247.0± 45.7
t-tau (pgml− 1) 62.2± 20.9 60.8± 21.4 64.3± 20.2 66± 22.3
p-tau (pgml− 1) 21.0± 8.0 20.6± 7.9 21.8± 8.5 21.3± 7.5
KBSI (ml per year) 6.0± 6.7 4.7± 5.4 7.5± 8.0 12.6± 10.5
VBSI (ml per year) 1.4± 1.6 1.1± 1.1 1.7± 2.1 2.5± 2.5
HBSI (ml per year) 0.05± 0.1 0.03± 0.09 0.07± 0.1 0.1± 0.06
MMSE decline from baseline to 12 months (points per year; n= 199) 0.1± 1.6 0.06± 1.3 0.2± 2 0± 2
% of individuals with minor allele rs7280100 12.0 13.2 11.1 0
Abbreviations: AD, Alzheimer’s disease; ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; CSF, cerebrospinal ﬂuid; HBSI, hippocampal
boundary shift integral; KBSI, whole brain boundary shift integral; MCI, mild cognitive impairment; MMSE, mini mental state examination; p-tau,
phosphorylated tau; t-tau, total tau; VBSI, ventricular boundary shift integral. Mean± s.d. provided unless stated.
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Table 2. Regression coefﬁcients for dependence of atrophy measures on CSF with control for the false discovery rate in subjects with low CSFAβ1-42
(⩽192 pgml− 1): adjusted for baseline brain volumes and tau; adjusted for baseline brain volumes, sex, age, APOE4 status, t-tau and p-tau; adjusted
for baseline brain volumes, sex, age, APOE4 status, t-tau, p-tau and baseline diagnosis
Brain atrophy Ventricular expansion Hippocampal atrophy
Regression
coefﬁcient
P Regression
coefﬁcient
P Regression
coefﬁcient
P
Adjusting for baseline brain volumes and t-tau
Alpha-1-Microglobulina (µgml− 1) − 3.17 0.002
Alpha-2-Macroglobulina (mgml− 1) − 4.31 0.006
Alpha-1-Antitrypsina (mgml− 1) − 0.19 0.018
Angiotensin-converting enzymea (ngml− 1) − 3.17 0.027
Angiopoietin-2a (ngml− 1) − 3.24 0.013
Apolipoprotein A-Ia (mgml− 1) − 2.39 0.018
Apolipoprotein C-IIIa(µgml− 1) − 2.02 0.042
Apolipoprotein Da (µgml− 1) − 3.54 0.003
Apolipoprotein Ea (µgml− 1) − 14.71 0.017 − 0.26 0.002
Apolipoprotein Ha (µgml− 1) − 2.99 0.004
AXL receptor tyrosine kinase (ngml− 1) − 1.59 0.01 − 0.40 0.018
Beta-2-Microglobulina (µgml− 1) − 3.87 0.018
Complement C3a (mgml− 1) − 3.80 0.003
CD-40 antigena (ngml− 1) − 5.20 0.004
Chromogranin-A (ngml− 1) − 0.05 0.008 − 0.013 0.009
Clusterina (µgml− 1) − 11.90 0.023 − 4.20 0.002
Cystatin-Ca (ngml− 1) 32.89 0.003 10.77 o0.001 0.34 0.019
Fibroblast growth factor 4a (pgml− 1) 3.45 0.022
Fibrinogena (mgml− 1) − 0.28 0.001
Heparin-binding EGF-like growth factora (pgml− 1) − 4.08 0.048
Hepatocyte growth factora (ngml− 1) − 2.59 0.048
Immunoglobulin Aa (mgml− 1) − 1.28 0.048
Interleukin-3a (ngml− 1) − 5.66 0.036 − 2.02 0.003
Insulin-like growth factor-binding protein (ngml− 1) − 0.017 0.004
Interferon gamma induced Protein 10a (pgml− 1) − 0.17 0.034
Lectin-like oxidized LDL receptor 1 (ngml− 1) − 0.30 0.006
Macrophage colony-stimulating factor 1a (ngml− 1) − 15.02 0.023 − 5.89 o0.001
Monokine induced by gamma interferona (pgml− 1) − 1.66 0.009
Neutrophil gelatinase-associated lipocalina (ngml− 1) − 2.49 0.018
N-terminal prohormone of brain natriuretic peptidea
(pgml− 1)
− 3.91 0.006 − 0.15 0.035
Placenta growth factora (pgml− 1) − 2.34 0.043
Pancreatic polypeptidea (pgml− 1) − 1.31 0.038
Serum amyloid P-componenta (µgml− 1) − 1.56 0.03
Stem cell factora (pgml− 1) − 0.18 0.027
Sex hormone-binding globulina (nmol/l) − 2.23 0.018
Thyroxine-binding globulina (µgml− 1) − 0.18 0.023
Tissue factora (µgml− 1) − 11.79 0.017 − 3.73 0.003
Trefoil factor 3a (µgml− 1) − 14.69 0.003 − 6.19 o0.001 − 0.178 0.002
Tissue inhibitor of metalloproteinases 1a (ngml− 1) − 3.88 0.015
Thrombomodulina (ngml− 1) − 2.52 0.045
Tumor necrosis factor receptor 2a (ngml− 1) − 4.05 0.007
TNF-related apoptosis-inducing ligand receptor 3a
(ngml− 1)
− 4.05 0.004
Vascular cell adhesion molecule-1a (ngml− 1) 3.46 0.018
Vascular endothelial growth factora (pgml− 1) − 21.32 0.004 − 6.86 o0.001 − 0.21 0.034
von Willebrand factora (µgml− 1) − 4.18 0.003
Adjusting for baseline brain volumes, sex, age, APOE4 status, tau and p-tau
Chromogranin-A (ngml− 1) − 0.05 0.009
Cystatin-Ca (ngml− 1) 32.58 0.009 0.35 0.034
Trefoil factor 3a (µgml− 1) − 16.43 0.009 − 4.46 0.03 − 0.23 0.001
Vascular endothelial growth factora (pgml− 1) − 20.09 0.023
Adjusting for baseline brain volumes, sex, age, APOE4 status, tau, p-tau and baseline diagnosis
Trefoil factor 3a (µgml− 1) − 0.21 0.007
N-terminal prohormone of brain natriuretic peptidea
(pgml− 1)
− 0.16 0.05
Abbreviations: CSF, cerebrospinal ﬂuid; EGF, endothelial growth factor; FDR, false discovery rate; p-tau, phosphorylated tau; t-tau, total tau. aTransformed data.
The statistics are presented for the transformed values (see Patients and Methods). Where data has been transformed, the units relate to data before
transformation. None of the analytes in Supplementary Table 1 was FDR signiﬁcant except those shown in this table. Regression coefﬁcients are shown for
those measures showing FDR signiﬁcant (5% level) associations. P-values are FDR (5% level) corrected.
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Analytes predicting cognitive decline
In subjects with CSF Aβ1-42 4192 pgml− 1, MMSE data at
12 months was available for all 87 subjects. The average decline
was not statistically signiﬁcantly different from zero and therefore
no further regression analyses were conducted in this group.
In subjects with CSF Aβ1-42 ≤ 192 pgml− 1, MMSE data at 0 and
12 months was available for 199 subjects, who declined on
average by 1.7 ± 3.5 points per year. Change in MMSE score at
12 months was strongly associated with change in whole brain
atrophy rate (regression coefﬁcient =− 0.15, Po0.001), ventricular
expansion (−0.49, Po0.001), and hippocampal atrophy rate.
(−11.16, Po0.001) Baseline levels of 11 CSF markers—AXL, ApoE,
CD-40 antigen, CgA, cystatin C, M-CSF, matrix metalloproteinase-2
(MMP-2), pregnancy-associated plasma protein, tissue factor, TFF3
and VEGF—were signiﬁcantly (without FDR correction) associated
with decline in MMSE at 12 months.
Predictive value
For those analytes that were FDR signiﬁcant in Table 2, the area
under the ROC curve for detecting between AD and control
groups were 0.59 (95% conﬁdence interval = 0.50, 0.69; CgA), 0.55
(0.45, 0.64; CysC), 0.55 (0.45, 0.65; TFF3) and 0.61 (0.52, 0.70; VEGF).
For reference, the corresponding estimated values for t-tau and
p-tau were 0.85 and 0.83, respectively.
DISCUSSION
Current models of AD pathogenesis suggest that deposition of
brain Aβ is a very early feature of AD, probably occurring before
the onset of AD-related neuronal loss (that is, neurodegenera-
tion).21 Rates of atrophy are signiﬁcantly increased in individuals
with established AD,22 mild cognitive impairment due to AD,23
and in asymptomatic brain amyloidosis,24 and correlate more
closely with cognitive decline and disease progression than
amyloid burden or rate of accumulation.25 In this study, using a
panel of analytes selected on the basis of relevance to a range of
different diseases including cancer and autoimmune disorders as
well as AD, we have identiﬁed a number of CSF biomarkers
associated with increased rates of neurodegeneration. In parti-
cular, our results suggest that in individuals with evidence for
brain amyloid deposition, CSF TFF3 level is associated both with
rate of cognitive decline and with rates of brain and hippocampal
atrophy and ventricular expansion.
Whilst we failed to ﬁnd an association between any analyte and
rate of atrophy in the amyloid negative group, after allowance for
Figure 2. Scatter plots of annualized atrophy (BSI—whole brain atrophy, HBSI—hippocampal atrophy, VSBI—ventricular expansion) against
analytes for those found to be associated (after FDR correction) with rates of volume change after adjusting for baseline volume, sex, age,
APOE4 status, t-tau and p-tau. *, transformed data. Where data has been transformed (TFF3, CysC, VEGF), the units relate to data before
transformation. AD, Alzheimer’s disease; CSF, cerebrospinal ﬂuid; BSI, boundary shift integral; FDR, false discovery rate; MCI, mild cognitive
impairment; p-tau, phosphorylated tau; t-tau, total tau; TFF3, trefoil factor 3.
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multiple comparisons in the amyloid-positive group in which we
adjusted for baseline brain volume and t-tau, we found that 45
analytes predicted increased ventricular expansion and ten
predicted rate of whole brain atrophy. Ventricular expansion
and brain atrophy are closely correlated,26 and as expected, all
ten factors predicting increased rates of whole brain atrophy also
predicted increased ventricular expansion. The higher precision
with which rate of ventricular change can be quantiﬁed18 is likely
to explain the larger number of analytes associated with
ventricular expansion compared with whole brain loss.
When we additionally adjusted for p-tau, ApoE status and sex,
adjusting for multiple comparisons, the number of factors
associated with rates of neurodegeneration in the amyloid-
positive group alone was considerably reduced, with only four
analytes showing an association with rates of neurodegenera-
tion. Lower levels of TFF3, VEGF and CrA and higher levels of
CysC were associated with increased rates of brain atrophy; lower
levels of TFF3 with increased ventricular expansion; and lower
levels of TFF3 and higher levels of CysC with increased rates of
hippocampal atrophy. In exploratory reverse stepwise analyses,
TFF3 was signiﬁcantly associated with rate of decline in all three
measures (Table 3), with an effect both independent from and at
least as great as CSF t-tau, which as expected, also (unadjusted)
predicted all three measures of neurodegeneration.27 The effect
of TFF3 persisted even once baseline p-tau, age, sex and APOE4
status had been accounted for (Table 3), and was still associated
with rate of hippocampal atrophy even once clinical diagnosis
(for example, control/MCI/AD) had been accounted for. These
results therefore support an association between CSF TFF3 and
increased rates of neurodegeneration independent of estab-
lished CSF biomarkers in individuals with amyloid deposition,
suggesting that CSF TFF3 may be a novel and valuable biomarker
of decline across the spectrum of AD.
Trefoil Factor 3 (TFF3)
Encoded by the TFF3 gene on chromosome 21, TFF3 is a protein
expressed by secretory epithelial cells principally in the gastro-
intestinal tract, and also in human hypothalamus and pituitary,28
and in the hippocampi, temporal cortices and cerebellum of
mice.29 Its function in the central nervous system is unknown,29
although TFF3 administration to mice has been reported to
improve memory.30 In the periphery, TFF3 has important roles in
NOTCH processing, and measurement of TFF3 in blood/urine/
faeces has been patented31 and used32 as a means of assessing
NOTCH-related side-effects in trials of gamma-secretase inhibi-
tors for the treatment of AD. To our knowledge, this is the ﬁrst
study to implicate TFF3 as a marker for neurodegeneration across
the AD spectrum, and furthermore to show that this is
independent of t-tau and p-tau: while there are few data on
which to suggest mechanisms, one intriguing possibility is that
this effect might in some way be mediated by alterations in
gamma-secretase processing. While numbers with a minor allele
were too small for anything more than an exploratory analysis,
the observation that genotype at the rs7280100, a candidate
locus associated with TFF3, is intriguing, and if replicated in
independent samples, suggests that CSF TFF3 and/or the
rs7280100 genotype may both help predict the rate of
neurodegeneration in individuals with amyloid pathology; and
that elucidating the function of TFF3 in the central nervous
system may provide insights into mechanisms inﬂuencing
neurodegeneration in the presence of brain amyloidosis.
Cystatin C (CysC), Vascular Endothelial Growth Factor (VEGF) and
Chromogranin-A (CgA)
Of the other three biomarkers emerging prominently from our
analyses, CysC colocalizes with β amyloid in amyloid plaques,
amyloid-laden vascular walls in cerebral amyloid angiopathy andT
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in Down’s syndrome and is typically reduced in AD CSF, with
multiple lines of evidence suggesting that it has protective roles in
AD principally due to inﬂuences on amyloid processing and
deposition.33 Conversely, increased CysC immunoreactivity is seen
in speciﬁc neuronal population in AD suggesting a role in
neurodegeneration;33 and in dopaminergic neurons, CysC has
been shown to have a role in neuronal injury-mediated microglial
activation and neurotoxicity.34 Our ﬁnding of a positive relation-
ship between rates of atrophy and CysC, in individuals in whom
amyloid deposition has already occurred, could therefore be
explained in terms of a harmful neuroinﬂammatory response
which results in neuronal damage. VEGF, abundantly expressed in
the CNS, has roles in modulation of angiogenesis, vascular
remodelling, repair, permeability and inﬂammation,35 and is
involved in microglial chemotaxis perhaps reﬂecting an early
response to amyloid deposition.36 Our ﬁnding of increased
atrophy with lower levels of CSF VEGF is consistent with VEGF
having a protective role in AD, and in keeping with reports that
transgenic AD mice with increased neuronal expression of VEGF
have a functional improvement in memory,35 suggests that
upregulation of VEGF may be a useful therapeutic strategy for
AD. Increased levels of CSF VEGF has been seen in individuals with
AD and vascular dementia compared with controls37—this could
also represent a protective response although VEGF levels were
not correlated with rate of atrophy or rate of cognitive decline.,
The neuroendocrine secretory protein CgA is the major protein of
large dense-core synaptic vesicles and may be a marker of
synaptic dysfunction.38 In one study lower CSF levels of CgA were
reported in the CSF of subjects with early onset sporadic or
familial Alzheimer’s disease,39 potentially in keeping with our
ﬁnding of inverse relationship between CgA level and increased
rates of brain atrophy and ventricular expansion.
In a previous study using this same panel of analytes, ten CSF
measures (ACE, CgA, AXL, TNF-related apoptosis-inducing ligand
receptor, CD-40, M-CSF, beta-2-microglobulin, stem cell factor,
CLU and IL-3) were shown to predict increased rates of amyloid
deposition in cognitively normal elderly individuals.13 When
comparing these results aiming at identifying markers predicting
rate of amyloid accumulation in healthy controls with ours
(assessing rate of neurodegeneration in individuals with likely
amyloid pathology) it is notable that in our initial analysis, we
identiﬁed ﬁve CSF analytes common to both: AXL, CgA, CLU, IL-3
and M-CSF; and including more stringent covariates that CgA
remained a consistent ﬁnding. While this could reﬂect that rates of
amyloid deposition and brain atrophy are highly correlated—as
would be predicted in the mid-phase of AD pathogenesis—this
would also be consistent with common mechanisms linking
amyloid deposition to subsequent neurodegeneration. However,
the fact that TFF3, CysC and VEGF were not identiﬁed in previous
analyses may suggest that these analytes may be exerting their
effects on neurodegeneration independent of amyloid deposition.
This study has a number of limitations. The number of subjects
is relatively small, particularly relative to the number of analytes,
and these ﬁndings thus require replication in other, larger cohorts.
However, we have used a statistical procedure to control for
multiple comparisons, indicating that the evidence for associa-
tions is moderately strong. While the use of reverse stepwise
analysis must be considered exploratory, the consistency with
which TFF3 emerges as a strong independent predictor of atrophy
is striking. However, it is perhaps less surprising that the same
analytes often predict all three atrophy measures, given that the
atrophy measures are mutually correlated. A relatively small
percentage of the variance in atrophy rates is explained by these
ﬁndings suggesting that other factors and other biomarkers
reﬂecting other independent pathways have yet to be identiﬁed,
noting that a certain proportion of variance may also be due to
measurement error. Including all individuals with low Aβ1-42 in
our analysis assumes that all patients with brain amyloidosis are
on the same neuropathological spectrum. While larger, more
homogeneous samples are required to assess whether the
relationships we show are driven by individuals with asympto-
matic amyloidosis, MCI or established AD, it is notable that the
relationship between TFF3 and hippocampal atrophy remains
even after adjusting for clinical diagnosis—which in this study
probably simply reﬂects different stages of disease.
We have identiﬁed a number of CSF markers that may be
associated with the rate of neurodegeneration in individuals with
amyloid deposition. These candidate biomarkers warrant further
investigation, potentially providing prognostic information for
patients; covariates for clinical trials; and insights into AD biology.
While several of the CSF biomarkers hint at immune-mediated
links between responses to amyloid deposition and brain volume
loss, the function of TFF3, which we found to be the single
strongest predictor of neurodegeneration across the spectrum of
brain amyloidosis, is unknown. Further studies to replicate these
ﬁndings and in particular to investigate the role of TFF3 in the
pathogenesis of AD are required.
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